Skip to main content
Premium Trial:

Request an Annual Quote

Kenneth Weg

Metamark Genetics has appointed Kenneth Weg as president and CEO. He succeeds Shawn Marcell, who resigned from his position to pursue other activities. Weg is a Metamark co-founder and current chairman of the board of directors. He has previously served as the president of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS), where he was responsible for overseeing all ethical pharmaceuticals and over-the-counter medicines on a global basis. Weg also served as vice chairman of the BMS board of directors. Before his work at BMS, he held the position of non-executive chairman of Millennium Pharmaceuticals. He has also served on the boards of Fox Chase Cancer Center and AVEO Pharmaceuticals and is a current member of Karyopharm's board of directors.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.